FDA approves expandable heart valve for children

Edwards’ Autus valve can be enlarged after implantation as a child grows, potentially reducing the need for replacement surgery.

Edwards’ Autus valve can be enlarged after implantation as a child grows, potentially reducing the need for replacement surgery.
The US Food and Drug Administration (FDA) has approved Edwards’ Autus Size-Adjustable Valve, an artificial pulmonary valve for children that can be enlarged after implantation, Engadget reported on October 2, 2026. Conventional artificial pulmonary valves typically need to be replaced with larger implants through successive operations as a child grows. Autus offers a way to enlarge the existing valve instead.
The pulmonary valve is on the right side of the heart. Its leaflets, or flaps, keep blood flowing in one direction. Conditions affecting this valve include stenosis, in which the valve is narrowed, and atresia, in which it does not form normally.
Autus can be implanted at a diameter as small as 13 millimeters in toddlers and preschool-aged children. It can later be expanded to a maximum diameter of 22 millimeters, comparable to the size of artificial valves intended for adults. For an older child, the valve can also be enlarged before implantation.
Expansion inside the body uses a balloon catheter—a thin tube with an inflatable balloon at its tip. Inflating the balloon enlarges the implanted valve. This still requires a catheter procedure: the valve does not grow automatically. The difference is that the procedure enlarges the existing implant rather than surgically replacing it with a larger one.
Autus uses polymer-based material for its leaflets rather than the animal-derived material used in conventional implants. Engadget reports that animal-derived leaflets tend to harden and break down faster in children, which can require further surgery.
According to Engadget, the FDA says one-year follow-up data suggest Autus may hold up better over time than other models. That finding does not establish lifelong durability or mean that every future operation can be avoided.
Detailed eligibility criteria, the number of patients studied and adverse-event results are not yet clear. How long the valve will last beyond the reported one-year follow-up remains an unresolved question.

The planned 12-week programme combines physical, psychological and relationship support with medication management for women whose pain persists despite treatment.
2 min

Two reviews’ estimates of fluoxetine’s benefits shrank when researchers removed a disputed trial. They seek a guideline review, not an end to prescribing.
3 min

The federal order prioritizes measurable pollution reductions but leaves coordination questions unanswered. Separately, Virginia tribes have withdrawn from formal participation after being denied full partner status.